QGEN and QIA Related Headlines
Go Back- Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
- Qiagen guides to at least 5% sales growth in 2026
- QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars
- QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
- QIAGEN Appoints Mark Stevenson to Supervisory Board
- Analysts consider potential Qiagen deal amid reported strategic review
- QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast
- QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
- QIAGEN to complete $500 million synthetic share repurchase by January 7
- QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million
- QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
- QIAGEN beats Q3 outlook, raises EPS target and announces $500M buyback
- QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
- QIAGEN to acquire Parse Biosciences for $225 million
- QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
- QIAGEN launches automated sexual assault DNA processing kit
- QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025
- QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing
- QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast
- QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio
- QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
- QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds
- QIAGEN issues $750 million convertible bonds due 2032
- QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds
- QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds
- QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability
- QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels
- QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast
- QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
- Qiagen (QGEN) and Gencurix partner to develop oncology assays for QIAcuityDx platform
- QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
- QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
QGEN and QIA Related Press Releases
Go Back- Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
- QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars
- QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
- QIAGEN Appoints Mark Stevenson to Supervisory Board
- QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast
- QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
- QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million
- QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
- QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
- QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
- QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025
- QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing
- QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast
- QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio
- QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
- QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds
- QIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible Bonds
- QIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible Bonds
- QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability
- QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels
- QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast
- QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
- QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
- QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
